Bebtelovimab Product Replacement Program

HHS announced a NEW Bebtelovimab Product Replacement Program is coming September 7, 2022. This aims to support providers who treat under and uninsured patients with commercially purchased Bebtelovimab. The criteria to participate in this program are:

- Has exhausted USG supply acquired through the HHS distribution program and has already purchased commercial Bebtelovimab.
- Attests to verifying the patient that received the commercially purchased treatment is under or uninsured.
- The fee to the under or uninsured patient has been waived or reduced (not to exceed CMS rate).

The replacement dose is from the commercial supply and can be used for any patient, regardless of insurance status. Requests for replacements can be made in HPoP. This information will be covered in our next webinar September 7, 2022 and posted on our VDH Therapeutics website.

Therapeutics Reporting in HPoP

When reporting your Therapeutics inventory and administrations in HPoP, think of what you are reporting as “boxes” when entering the quantity into HPoP. For administrations, enter the number of “boxes” utilized for the administration. For inventory, enter the number of “boxes” that you have on hand in the facility.

<table>
<thead>
<tr>
<th>Therapeutic</th>
<th>Size</th>
<th>Inventory &amp; Administrations (Report As)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paxlovid</td>
<td>1 Course = 1 Box = 30 pills</td>
<td>1 Box</td>
</tr>
<tr>
<td>Paxlovid Renal</td>
<td>1 Course = 1 Box = 20 pills</td>
<td>1 Box</td>
</tr>
<tr>
<td>Lagervrio (molnupiravir)</td>
<td>1 Course = 1 Bottle = 40 pills</td>
<td>1 Box</td>
</tr>
<tr>
<td>EVUSHELD</td>
<td>1 Dose = 2 Boxes = 300mg of tixagevimab &amp; 300mg cilgavimab</td>
<td>2 Boxes</td>
</tr>
<tr>
<td>Bebtelovimab</td>
<td>1 Dose = 1 box = 175mg of Bebtelovimab</td>
<td>1 Box</td>
</tr>
</tbody>
</table>

If you feel that your facility may have incorrectly reported your on hand inventory or your administrations, please reach out to us at the COVID-19 Therapeutics Inbox covid19therapeutics@vdh.virginia.gov and we can assist you with getting your information corrected in HPoP.
Total number of Paxlovid courses given in Virginia exceeds 100K!

We are pleased to report from December 28, 2021 to August 31, 2022, there have been **107,229** courses of Paxlovid administered across the Commonwealth! While this is good news, we continue to encourage our prescribers to develop a plan for high risk patients before they are COVID-19 positive and utilize screening tools to evaluate for Paxlovid use.

Paxlovid is available in ample supply without any constraints and remains the preferred COVID-19 therapy for patients at high risk of progressing to severe COVID-19. Notably, Paxlovid is 88-90% effective in reducing the risk of hospitalization or death as a result of COVID-19. While there are significant drug-drug interactions associated with Paxlovid, there are a variety of tools and resources for prescribers to assist in managing interactions.

### Total Allocations to Therapeutic Administration Sites (08/19/2022 - 09/01/2022):

<table>
<thead>
<tr>
<th>Therapeutic (mAB &amp; OAV*)</th>
<th>Central</th>
<th>Eastern</th>
<th>Northern</th>
<th>Northwest</th>
<th>Southwest</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bebtelovimab*</td>
<td>60</td>
<td>65</td>
<td>100</td>
<td>105</td>
<td>170</td>
<td>500</td>
</tr>
<tr>
<td>Evusheld</td>
<td>408</td>
<td>168</td>
<td>168</td>
<td>221</td>
<td>120</td>
<td>1085</td>
</tr>
<tr>
<td>Lagevrio (Molnupiravir)</td>
<td>0</td>
<td>48</td>
<td>48</td>
<td>72</td>
<td>72</td>
<td>240</td>
</tr>
<tr>
<td>Paxlovid</td>
<td>20</td>
<td>180</td>
<td>60</td>
<td>460</td>
<td>280</td>
<td>1000</td>
</tr>
<tr>
<td>Renal Paxlovid</td>
<td>15</td>
<td>25</td>
<td>10</td>
<td>50</td>
<td>15</td>
<td>115</td>
</tr>
</tbody>
</table>

*Oral Antiviral numbers presented do not include those allocated to Community Pharmacy Enhanced Services Network. These Oral Antiviral courses were bulk ordered and distribution to individual site locations is managed by respective Federal Retail Pharmacy Therapeutic Program (FRPTP) partners, VDH does not have visibility of course distribution to each region.

*Bebtelovimab allocations and administrations is only for USG-supply and not for commercially purchased Bebtelovimab

*Please reference the Outpatient Therapeutic Portfolio- Jurisdiction Allocations for more detail.
NEW! Join the Waitlist for Redistributed USG-Supplied Bebtelovimab

VDH seeks to redistribute USG-supplied Bebtelovimab amongst providers who volunteer to share excess USG supply. The USG recommends the USG-supplied Bebtelovimab be used for the under and uninsured population. To prioritize the under and uninsured population, requests should only be made on the VDH home page if this is a population that you or your organization serves.

*Please note:* By submitting your request to be added to the [waitlist](#), there is no guarantee to receive redistributed USG-supplied Bebtelovimab.

**Redistribution**

VDH can redistribute therapeutics within our Commonwealth. Any providers wishing to make their therapeutics available for transfer can do so by clicking the link “Redistribute Excess Therapeutics” on the VDH home page. The VDH Therapeutics team will prioritize these available therapeutics before pulling from federal supplies whenever it is advantageous to do so.

Listen to the Redistribution webinar [here](#). The Redistribution discussion starts at 8:55.

**Resources and Tools**

**Link to Sign Up for the Newsletter:**

Did your colleague share this newsletter with you, and you’d like to sign up to receive it directly? Do you know of a colleague that would benefit from receiving information on therapeutics from VDH? Click [here](#) to sign up!

**VDH Therapeutics Website for Healthcare Providers**

Check out the VDH Therapeutics webpage [here](#). Reach out to COVID19Therapeutics@vdh.virginia.gov for questions, comments, or feedback on information you’d like to see.

**COVID-19 Therapeutics Webinars and Open Forum Calls for Providers**

VDH is continuing to facilitate webinars and open forums monthly. See below for links to [register](#)!

September 7 COVID-19 Therapeutics Healthcare Provider Webinar: Register [here](#).
September 21 VDH Healthcare Provider Open Forum: Register [here](#).

Other resource links:

- [VDH: COVID-19 Therapeutics FAQs for Providers](#)
- [VDH: Guidance on Expiring & Expired Therapeutics](#)
- [VDH: EVUSHELD Fact Sheet for Providers](#)
- [VDH: Lagevrio (Molnupiravir) Prescribing Checklist](#)
- [VDH: Paxlovid Prescribing Checklist](#)
- [VDH: Paxlovid Prescribing Checklist- Pharmacists](#)
- [HHS: ASPR Test to Treat Fact Sheet](#)
- [Treatment of Monkeypox: Information for Virginia Healthcare Providers](#)

Find where to access therapeutics [here](#).